The WHO predicts hearing loss will impact 1 in 10 people by 2050. Medical devices are the standard of care, but they are ineffective for many people.
Despite a prevalence greater than cancer or diabetes, there are currently no treatments available to treat the underlying cellular dysfunction which is the root cause of hearing loss.
Lipid nanoparticle-based mRNA therapeutics were spectacularly validated as a mass market medicine through the COVID-19 pandemic. We believe the time is now to create the world’s first mass market medicine for hearing loss.
Company Details
- Employees
- 3
- Founded
- 2024
- Address
- Millscitech Park, Cambridge,cambridgeshire Cb22 5hx,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.camgenetx.com
- Keywords
- mRNA, hearing loss, lipid nanoparticles, LNP.
- HQ
- Cambridge, Cambridgeshire
Camgene Therapeutics Questions
Camgene Therapeutics's website is http://www.camgenetx.com
Camgene Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/camgenetx
Camgene Therapeutics has
3 employees.
View email and phone details for 3
employees at Camgene Therapeutics.
Camgene Therapeutics's industry is
Biotechnology Research
Camgene Therapeutics's top competitors are
Camgenetix,
Creasallis,
Ignota Labs,
Greywolf Therapeutics,
Tessellate Bio,
Ambrose Healthcare,
Eyebio,
Aviadobio,
Mesox,
Vitarka Therapeutics.
Camgene Therapeutics's categories are Biotechnology Research
Camgene Therapeutics's founding year is 2024
